---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-031695"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T05:54:42.148952+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics presents updated proof-of-concept data for BIVV003 and giroctocogene fitelparvovec at ASH

## Summary
- BIVV003 in sickle cell disease: 3 of 4 Group 1 patients maintained HbF >30% with no severe VOCs up to 30 months.
- Group 2 Patient 5 achieved HbF 45% and total Hb 12.4 g/dL at week 26 using improved manufacturing.
- Hemophilia A gene therapy: highest dose cohort had zero annualized bleeding rate in first year post-infusion.
- Mean FVIII activity at week 156 was 25.5% of normal in highest dose cohort with no inhibitor development.
- No treatment-related serious adverse events for BIVV003; one grade 3 hypotension event in hemophilia A study resolved.

## SEC filing metadata
- accession: 0001628280-22-031695
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/0001628280-22-031695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/sgmo-20221210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-031695
- JSON: https://secwatch.observer/filing/0001628280-22-031695.json
- Plain text: https://secwatch.observer/filing/0001628280-22-031695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.